Ann: MYX announces two additional patents for Nextstellis granted, page-6

Quite right Daicos, it takes time to build a sustainable profitable company. This is an extension of a previous announcement on the IP for Nextstellis and is probably not market sensitive but does offer protection until 2036.

I noted several things within the announcement, first a commentary from the new EVP Womens Health , Lynn Sullivan, who has been with the company since January to build a bigger women's health business. She's a highly regarded executive, having previously worked as Senior VP for Novo Nordisk (huge company) and has been credited with building a multi-billion $ revenue business with anti obesity drugs for Novo Nordisk. Hope she can do the same for us.

She also mentioned that Nexstellis is the highest growing branded OC from September 2023 to March 2024, this, to me indicates that growth has probably been restored to previous levels of 8 to 11% month on month. We'll have to wait and see on that. There's also a brief, but not insignificant comment, about Nexstellis being a low impact natural Estrogen with low impact on the liver among other things. (A strong differentiation from other OC's in my view).

I think we will get a market sensitive announcement either Monday or Tuesday as the CEO and the CFO will be making a presentation in New York in the early hours of Tuesday and will probably contain a market update for the third quarter.